Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study): effect of regulatory warnings - PubMed
11 hours ago
- #JAK inhibitors
- #drug safety
- #rheumatoid arthritis
- Study examines the impact of regulatory warnings on JAK inhibitor (JAKi) prescriptions for rheumatoid arthritis (RA) from 2015 to 2024.
- Data from 12 national registries analyzed 55,365 treatment courses (12,559 JAKi and 42,806 other bDMARDs) in 40,019 RA patients.
- JAKi use increased from <1% in 2015 to >20% by 2024, with slowdowns after FDA (2019) and EMA (2022) warnings.
- Tofacitinib most affected by warnings, with declines in initiation and increases in discontinuation.
- Upadacitinib initiations declined and discontinuations increased after the ORAL Surveillance trial publication.
- Baricitinib use less impacted by safety signals; filgotinib use steadily increased.
- At-risk populations (age ≥65 with cardiovascular risk factors) saw higher JAKi discontinuation rates post-2019 EMA warning.
- Regulatory safety communications significantly influenced real-world JAKi prescribing patterns.